Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lung-AK104 Study: Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage Lll Non-Small Cell Lung Cancer

NCT06448910 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT06448910
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06448910 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lung-AK104 Study: Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage Lll Non-Small Cell Lung Cancer
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 1, 2024
Completion date
June 30, 2027
Enrollment
41 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced lung carcinoma, nsclc